ox-LDL/LOX-1信号通路在糖尿病相关疾病中的研究进展

doi:10.3969/j.issn.1004-583X.2023.01.013

摘要/Abstract

摘要：

氧化型低密度脂蛋白(oxidized low density lipoprotein,ox-LDL)是低密度脂蛋白胆固醇(low density lipoprotein cholesterol, LDL-C)的氧化修饰产物,具有很强的细胞毒性,是诱发脂毒性的主要异常脂类。植物血凝素样氧化型低密度脂蛋白受体1(lectin-like oxidized low-density lipoprotein receptor-1,LOX-1)是一种分子量为50 kDa跨膜糖蛋白。研究表明,ox-LDL/LOX-1信号通路在糖尿病并发症、主动脉粥样硬化、类风湿性关节炎及肿瘤等疾病中具有重要的病理生理作用,特别是糖尿病相关疾病的进展与ox-LDL/LOX-1信号通路的激活或表达上调密切相关。本文通过对ox-LDL/LOX-1信号通路在糖尿病相关疾病中的研究进展进行综述,旨在为糖尿病相关疾病的诊治提供理论依据。

中图分类号:

R587.1

仇菊梅, 张琦, 刘静, 余静, 张雅娟. ox-LDL/LOX-1信号通路在糖尿病相关疾病中的研究进展[J]. 临床荟萃, 2023, 38(1): 79-83.

导出引用管理器 EndNote|Ris|BibTeX

链接本文: https://huicui.hebmu.edu.cn/CN/10.3969/j.issn.1004-583X.2023.01.013

https://huicui.hebmu.edu.cn/CN/Y2023/V38/I1/79

参考文献 40

[1]	Sun H, Saeedi P, Karuranga S, et al. IDF Diabetes Atlas: Global, regional and country-level diabetes prevalence estimates for 2021 and projections for 2045[J]. Diabetes Res Clin Pract, 2022, 183:109119. doi: 10.1016/j.diabres.2021.109119 URL
[2]	White NH, Pan Q, Knowler WC, et al. Risk factors for the development of retinopathy in prediabetes and type 2 diabetes: The diabetes prevention program experience[J]. Diabetes Care, 2022, 45(11):2653-2661. doi: 10.2337/dc22-0860 pmid: 36098658
[3]	Sharma G, Ashhar MU, Aeri V, et al. Development and characterization of late-stage diabetes mellitus and -associated vascular complications[J]. Life Sci, 2019, 216: 295-304. doi: S0024-3205(18)30710-0 pmid: 30408473
[4]	Aoyama T, Sawamura T, Furutani Y, et al. Structure and chromosomal assignment of the human lectin-like oxidized low-density-lipoprotein receptor-1 (LOX-1) gene[J]. Biochem J, 1999, 339(Pt 1):177-184. doi: 10.1042/bj3390177 URL
[5]	Jin P, Cong S. LOX-1 and atherosclerotic-related diseases[J]. Clin Chim Acta, 2019, 491:24-29. doi: S0009-8981(19)30019-1 pmid: 30639239
[6]	de Alwis N, Beard S, Binder NK, et al. LOX-1 expression is reduced in placenta from pregnancies complicated by preeclampsia and in hypoxic cytotrophoblast[J]. Pregnancy Hypertens, 2021, 25:255-261. doi: 10.1016/j.preghy.2021.07.243 pmid: 34325289
[7]	Stankova TR, Delcheva GT, Maneva AI, et al. Serum levels of carbamylated LDL, nitrotyrosine and soluble lectin-like oxidized low-density lipoprotein receptor-1 in poorly controlled type 2 diabetes mellitus[J]. Folia Med (Plovdiv), 2019, 61(3): 419-425. doi: 10.3897/folmed.61.e39343 pmid: 32337929
[8]	Ackermann K, Bonaterra GA, Kinscherf R, et al. Growth differentiation factor-15 regulates oxLDL-induced lipid homeostasis and autophagy in human macropha ges[J]. Atherosclerosis, 2019, 281:128-136. doi: S0021-9150(18)31540-5 pmid: 30658188
[9]	Díaz-Ruiz M, Martínez-Triguero ML, López-Ruiz A, et al. Metabolic disorders and inflammation are associated with familial combined hyperlipemia[J]. Clin Chim Acta, 2019, 490:194-199. doi: S0009-8981(18)30486-8 pmid: 30201373
[10]	Rawshani A, Rawshani A, Franzén S, et al. Risk factors, mortality, and cardiovascular outcomes in patients with type 2 diabetes[J]. N Engl J Med, 2018, 379 (7):633-644. doi: 10.1056/NEJMoa1800256 URL
[11]	GRADE Study Research Group, Nathan DM, Lachin JM, et al. Glycemia reduction in type 2 diabetes-microvascular and cardiovascular outcomes[J]. N Engl J Med, 2022, 387(12):1075-1088. doi: 10.1056/NEJMoa2200436 URL
[12]	Fazlali M, Kharazmi F, Kamran M, et al. Effect of oral magnesium sulfate administration on lectin-like oxidized low-density lipoprotein receptor-1 gene expression to prevent atherosclerosis in diabetic rat vessels[J]. J Diabetes Inve stig, 2019, 10(3):650-658.
[13]	Qian W, Cai X, Qian Q, et al. Astragaloside IV protects endothelial proge nitor cells from the damage of ox-LDL via the LOX-1/NLRP3 inflammasome pathway[J]. Drug Des Devel Ther, 2019, 13: 2579-2589. doi: 10.2147/DDDT.S207774 URL
[14]	Tiong YL, Ng KY, Koh RY, et al. Melatonin inhibits high glucose-induced ox-LDL/LDL expression and apoptosis in human umbilical endothelial cells[J]. Horm Mol Biol Clin Investig, 2020, 41(4).
[15]	Mortazavi-Jahromi SS, Alizadeh S, Javanbakht MH, et al. Cardioprotective ef fect of β-d-mannuronic acid (M2000) as a novel NSAID on gene expression of oxLDL scavenger receptors in the experimental diabetic model[J]. Immunopharmacol Imm unotoxicol, 2018, 40(4):284-289.
[16]	Abbasnezhad A, Niazmand S, Mahmoudabady M, et al. Nigella sativa L. seed regulated eNOS, VCAM-1 and LOX-1 genes expression and improved vasoreactivity in aorta of diabetic rat[J]. J Ethnopharmacol, 2019, 228:142-147. doi: S0378-8741(18)30582-8 pmid: 30223051
[17]	Marshall SM. The pancreas in health and in diabetes[J]. Diabetologia, 2020, 63(10):1962-1965. doi: 10.1007/s00125-020-05235-z pmid: 32894305
[18]	Volpe CMO, Villar-Delfino PH, Dos Anjos PMF, et al. Cellular death, reactive oxygen species (ROS) and diabetic complications[J]. Cell Death Dis, 2018, 9(2): 119. doi: 10.1038/s41419-017-0135-z pmid: 29371661
[19]	Szkudelski T. The mechanism of alloxan and streptozotocin action in B cells of the rat pancreas[J]. Physiol Res, 2001, 50(6):537-546. pmid: 11829314
[20]	Xu K, Liu X, Yin D, et al. PP2A alleviates oxidized LDL-induced endothelial dysfunction by regulating LOX-1/ROS/MAPK axis[J]. Life Sci, 2020, 243:11 7270.
[21]	Bayatpoor ME, Mirzaee S, Karami Abd M, et al. Crocin treatment decreased pancreatic atrophy, LOX-1 and RAGE mRNA expression of pancreas tissue in chol esterol-fed and streptozotocin-induced diabetic rats[J]. J Complement Integr Med, 2019, 17(2): /j/jcim. 2020.17. issue-2/jcim-2019-0117/jcim-2019-0117. xml.
[22]	Islam J, Lee HJ, Yang SH, et al. Expansion of myeloid-derived suppressor cells correlates with renal progression in type 2 diabetic nephropathy[J]. Immune Netw, 2020, 20(2): e18. doi: 10.4110/in.2020.20.e18 URL
[23]	Roumeliotis S, Roumeliotis A, Georgianos PI, et al. Oxidized LDL is associated with eGFR decline in proteinuric diabetic kidney disease: A cohort study[J]. Oxid Med Cell Longev, 2021, 2021:2968869.
[24]	Zhou X, Liu R, Duan S, et al. High glucose enhances oxLDL-induced apoptosis in human renal proximal tubular epithelial cells largely via inducing lectin-like ox-LDL receptor-1[J]. Pharmacology, 2016, 98(1-2):20-28. doi: 10.1159/000444934 pmid: 27003929
[25]	郭亚玲, 陈卫东, 杨萍, 等. LOX-1、VCAM-1在糖尿病肾病动脉粥样硬化大鼠中的表达及普罗布考的影响[J]. 国际泌尿系统杂志, 2014, 34(2):177-183.
[26]	宋光明, 柴可夫, 杜月光. LOX-1和炎症因子在糖尿病肾病中的作用及糖肾颗粒早期干预研究[J]. 内蒙古中医药, 2016, 35(1):137-139.
[27]	杜月光, 钱俊文, 宋光明, 等. LOX-1在2型糖尿病大鼠肾小管间质中的表达及其意义[J]. 中国病理生理杂志, 2013, 29(1):50-55.
[28]	Tanase DM, Gosav EM, Costea CF, et al. The intricate relationship between type 2 diabetes mellitus (T2DM), insulin resistance (IR), and nonalcoholic fatty liver disease (NAFLD)[J]. J Diabetes Res, 2020, 2020:3920196.
[29]	Heidari F, Rabizadeh S, Mansournia MA, et al. Inflammatory, oxidative stress and anti-oxidative markers in patients with endometrial carcinoma and diabetes[J]. Cytokine, 2019, 120:186-190. doi: S1043-4666(19)30122-X pmid: 31100682
[30]	Ma S, Bai Z, Wu H, et al. The DPP-4 inhibitor saxagliptin ameliorates ox-LDL-induced endothelial dysfunction by regulating AP-1 and NF-κB[J]. Eur J Pharmacol, 2019, 851:186-193. doi: S0014-2999(19)30016-0 pmid: 30639312
[31]	胡丽叶, 宋光耀, 朱旅云, 等. 2型糖尿病大鼠肝脏LOX-1、eNOS、PPARγ蛋白表达及罗格列酮的干预作用[J]. 临床误诊误治, 2015, 28(6):109-113.
[32]	Chen CM, Juan SH, Pai MH, et al. Hyperglycemia induces epithelial-mesenchymal transition in the lungs of experimental diabetes mellitus[J]. Acta Histochem, 2018, 120(6):525-533. doi: 10.1016/j.acthis.2018.06.004 URL
[33]	Korkmaz FT, Shenoy AT, Symer EM, et al. Lectin-like oxidized low-density lipoprotein receptor 1 attenuates pneumonia-induced lung injury[J]. JCI Insight, 2022, 7(23): e149955. doi: 10.1172/jci.insight.149955 URL
[34]	Hu C, Dandapat A, Sun L, et al. Regulation of TGFbeta1-mediated collagen formation by LOX-1: Studies based on forced overexpression of TGFbeta1 in wild-type and lox-1 knock-out mouse cardiac fibroblasts[J]. J Biol Chem, 2008, 283(16):10226-10231. doi: 10.1074/jbc.M708820200 pmid: 18182394
[35]	Zou XZ, Gong ZC, Liu T, et al. Involvement of epithelial-mesenchymal transition afforded by activation of LOX-1/ TGF-β1/KLF6 signaling pathway in diabetic pulmonary fibrosis[J]. Pulm Pharmacol Ther, 2017, 44:70-77. doi: 10.1016/j.pupt.2017.03.012 URL
[36]	El-Wakeel LM, Fouad FA, Saleem MD, et al. Efficacy and tolerability of sildenafil/l-arginine combination relative to sildenafil alone in patients with organic erectile dysfunction[J]. Andrology, 2020, 8(1):143-147. doi: 10.1111/andr.12671 pmid: 31267684
[37]	Bajaj HS, Gerstein HC, Rao-Melacini P, et al. Erectile function in men with type 2 diabetes treated with dulaglutide: An exploratory analysis of the REWIND placebo-controlled randomised trial[J]. Lancet Diabetes Endocrinol, 2021, 9 (8):484-490. doi: 10.1016/S2213-8587(21)00115-7 URL
[38]	杨志刚, 程宛钧, 谢瑜, 等. 丹瓜方联合枸橼酸西地那非片治疗痰瘀型2型糖尿病勃起功能障碍的临床观察[J]. 中西医结合研究, 2019, 11(2):93-95.
[39]	Wang JS, Li X, Chen ZL, et al. Effect of leech-centipede medicine on improving erectile function in DIED rats via PKC signalling pathway-related molecules[J]. J Ethnopharmacol, 2021, 267:113463. doi: 10.1016/j.jep.2020.113463 URL
[40]	Li X, Feng JL, Chen ZL, et al. Mechanism by which Huoxue Tongluo Qiwei Decoction improves the erectile function of rats with diabetic erectile dysfunction[J]. J Ethnopharmacol, 2022, 283:114674. doi: 10.1016/j.jep.2021.114674 URL